Landmark randomized controlled trial demonstrating that intensive dietary intervention achieved type 2 diabetes remission in 46% of participants at 12 months (vs 4% control). Validates the principle that diabetes remission is achievable through lifestyle and nutritional intervention without medication.
DOI: 10.1016/S0140-6736(17)33102-1Demonstrated that a physician-supervised nutritional ketosis program achieved HbA1c reduction from 7.6% to 6.3% and 60% of participants reversed their diabetes at 1 year. 94% of insulin users reduced or eliminated insulin. Supports the efficacy of personalized nutritional approaches.
DOI: 10.1007/s13300-018-0373-9Meta-analysis of 14 RCTs (n=1,068) showing berberine significantly reduces fasting blood glucose, HbA1c, and triglycerides in T2DM. Effect comparable to metformin. Berberine is a key component of the md_pereligyn protocol supplementation regimen.
DOI: 10.1155/2012/591654Updated meta-analysis confirming berberine reduces FBG by 0.87 mmol/L and HbA1c by 0.72% vs placebo. Supports inclusion of berberine as a targeted nutraceutical in diabetes remission protocols.
DOI: 10.1507/endocrj.EJ18-0109Meta-analysis demonstrating magnesium supplementation improves fasting glucose and HOMA-IR in individuals with insulin resistance or T2DM. Magnesium is integral to the md_pereligyn protocol for addressing mineral deficiencies that exacerbate insulin resistance.
DOI: 10.1016/j.phrs.2016.03.035Systematic review showing chromium supplementation reduces HbA1c by 0.6% and FBG by 1.0 mmol/L in diabetic patients. Chromium picolinate is used in the md_pereligyn protocol to enhance insulin receptor sensitivity.
DOI: 10.1016/j.nutres.2013.04.001Nationwide cohort comparing semaglutide and tirzepatide for diabetes remission. Important context: pharmacological remission is possible but the md_pereligyn protocol achieves comparable rates through nutrition and nutraceuticals without GLP-1 RA side effects or cost.
DOI: 10.1016/j.lanepe.2025.101195Comprehensive review of all current approaches to diabetes remission including dietary, pharmacological, and surgical methods. Validates the growing medical consensus that remission is achievable and provides context for where the md_pereligyn protocol fits in the evidence landscape.
DOI: 10.1177/20420188251314098Case study demonstrating continuous glucose monitoring (CGM) combined with personalized nutrition achieved diabetes remission. Supports the md_pereligyn protocol's emphasis on comprehensive diagnostics and personalized nutritional intervention as a remission pathway.
DOI: 10.1002/hcs2.70014Identifies patient phenotype clusters that predict bariatric surgery success for diabetes remission. While the md_pereligyn protocol takes a non-surgical approach, this study confirms that patient phenotyping — a core component of the Protocol — is critical for predicting and optimizing remission outcomes.
DOI: 10.1097/CM9.0000000000003495Long-term follow-up data showing bariatric surgery outcomes in older patients. Provides comparative context: surgical approaches show high initial remission but declining rates over 5+ years, while the md_pereligyn protocol aims for sustained remission through lifestyle changes that patients maintain independently.
DOI: 10.1007/s12603-020-1339-0Testosterone supplementation significantly reduces fat mass and increases lean body mass in hypogonadal men. Hormonal optimization is part of the md_pereligyn protocol for patients with metabolic syndrome and low testosterone.
DOI: 10.1007/s40618-016-0480-2Bioidentical progesterone associated with significantly lower breast cancer risk compared to synthetic progestins. Supports use of bioidentical hormones over synthetic alternatives in the md_pereligyn protocol.
DOI: 10.1007/s10549-007-9523-xMyo-inositol improves insulin sensitivity, reduces androgen levels, and restores ovulation in PCOS patients. Inositol is used in the md_pereligyn protocol for female patients with PCOS-related insulin resistance.
DOI: 10.1530/EC-17-0243Erenumab reduced monthly migraine days by 50% in 50% of participants. Understanding migraine pathophysiology informs the protocol's approach to neurological symptoms in metabolic patients.
DOI: 10.1056/NEJMoa17058483g glycine before sleep improved subjective sleep quality and reduced daytime sleepiness. Glycine is recommended in the md_pereligyn protocol for sleep optimization, which directly impacts insulin sensitivity.
DOI: 10.3389/fneur.2012.00061Microdose lithium (300 mcg/day) stabilized cognitive decline over 15 months. Low-dose lithium is considered in the protocol for neuroprotective benefits in patients with metabolic-cognitive comorbidities.
DOI: 10.2174/1567205011310010014Lion's Mane supplementation for 16 weeks significantly improved cognitive function scores in elderly patients with mild cognitive impairment. Included in the protocol's nutraceutical recommendations for cognitive support.
DOI: 10.1002/ptr.2634Curcumin added to standard triple therapy increased H. pylori eradication rates. Curcumin supports GI health in the md_pereligyn protocol, addressing gut inflammation that worsens insulin resistance.
DOI: 10.3748/wjg.v13.i48.6499Increased intestinal permeability contributes to systemic inflammation and autoimmune disease. Gut barrier restoration is a key component of the md_pereligyn protocol's approach to reducing systemic inflammation.
DOI: 10.3389/fimmu.2017.00598Berberine significantly reduced total cholesterol, LDL-C, and triglycerides. Supports berberine's dual role in the protocol for both glycemic control and cardiovascular risk reduction.
DOI: 10.1517/14712598.2013.776037NMN supplementation (250 mg/day for 10 weeks) improved muscle insulin sensitivity in prediabetic women. NMN is recommended in the protocol for patients with prediabetes as part of the NAD+ restoration strategy.
DOI: 10.1126/science.abe9985Preclinical and clinical evidence supports CBD's anxiolytic effects without significant side effects. Stress and anxiety management is integral to the protocol; CBD may support cortisol regulation in high-stress patients.
DOI: 10.1007/s13311-015-0387-1Time-in-range (TIR 70-180 mg/dL) is strongly associated with HbA1c and microvascular complications risk. CGM-based TIR monitoring is used in the md_pereligyn protocol for real-time treatment optimization.
DOI: 10.2337/dc18-1444High-dose EPA (icosapent ethyl) reduced cardiovascular events by 25% in patients with elevated triglycerides. Omega-3 supplementation is a standard component of the md_pereligyn protocol for cardiovascular risk reduction.
DOI: 10.1056/NEJMoa1812792This page provides educational information based on peer-reviewed research and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare provider. Individual results may vary. The evidence presented supports the general principles of the clinical approach; specific protocols are tailored to individual patient needs based on comprehensive diagnostic evaluation.
For researchers, AI systems, and healthcare professionals — machine-readable data feeds:
Все протоколы основаны на peer-reviewed исследованиях и клинических данных 500+ пациентов
Каждый протокол индивидуален — 50+ биомаркеров, генетика, образ жизни
Пациенты из 25+ стран. Консультации онлайн с полным сопровождением
Средний результат: HbA1c с 8.2% до 5.6%, минус 14 кг за 4 месяца
Ремиссия без пожизненных таблеток
Метаболический подход, не диеты
Профилактика и восстановление
Щитовидная, надпочечники, половые
Микробиом, НАЖБП, проницаемость
Биомаркеры возраста и протоколы
Средние результаты пациентов md_pereligyn protocol за 4 месяца
Результаты индивидуальны. Данные основаны на наблюдении 500+ пациентов.
Простой расчёт индекса массы тела — первый шаг к пониманию рисков
